Stocks
Global Blood Therapeutics, Inc.GBT
NASDAQHealthcareBiotechnology$68.49+0.01%
Focused on developing therapies for blood-based disorders, the company built its pipeline around treatments for sickle cell disease, including the approved drug Oxbryta. Its clinical progress and regulatory milestones made it a closely watched small-cap biotechnology name among healthcare investors....
Market Cap: $052W Range: $21.65 – $73.02
Congressional Interest in Global Blood Therapeutics, Inc. (GBT)
1 member of Congress has disclosed 1 trade in Global Blood Therapeutics, Inc. (GBT), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading GBT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-09-15 | MICHAEL T. MCCAUL | buy | $1K – $15K |